Hyperuricemia With Diabetes Compounds ESKD, Death Risks
A study conducted in Taiwan is the first to show that hyperuricemia is as risky as diabetes in contributing to ESKD and death risk in patients with stage 3 to 5 CKD.
A study conducted in Taiwan is the first to show that hyperuricemia is as risky as diabetes in contributing to ESKD and death risk in patients with stage 3 to 5 CKD.
Study findings suggest the nephroprotective effects of both drug classes are complementary.
Study findings highlight an “unmet need” for newer therapies.
Investigators focused on the prognostic value of the uremic solutes asymmetric dimethylarginine, symmetric dimethylarginine, and trimethylamine-N-oxide.
Mendelian randomization study shows causal association between higher body mass index and increased risk for diabetic nephropathy
Diabetes is a possible risk factor for major bleeding complications after percutaneous renal biopsy, according to investigators.
Affordability of SGLT2i may contribute to the low prescription rate in CKD.
Atrasentan lowers the risk for a composite of kidney failure, doubling of serum creatinine, or kidney death consistently across subgroups of urinary albumin-creatinine ratio and estimated glomerular filtration rate.
SGLT2 inhibitors are associated with an initial dip in eGFR, so nephrologists need to monitor kidney function.
Obesity rates in glomerular disease have multiplied more than 10-fold over the last 40 years.